Healthcare Equipment and Supplies
Company Overview of Amedica Corporation
Amedica Corporation, a commercial-stage biomaterial company, develops, manufactures, and sells a range of medical devices based on its silicon nitride technology platform in the United States, Europe, and South America. It offers Valeo silicon nitride interbody spinal fusion devices for use in the cervical and thoracolumbar areas of the spine; and a line of non-silicon nitride spinal fusion products. The company also develops femoral heads for use in total hip replacements; and femoral condyle components for use in total knee replacements. It markets and sells its products to surgeons and hospitals directly, as well as through a network of independent sales distributors. Amedica Corporation ...
1885 West 2100 South
Salt Lake City, UT 84119
Founded in 1996
Key Executives for Amedica Corporation
Chairman of the Board, Chief Executive Officer and President
Total Annual Compensation: $79.4K
Compensation as of Fiscal Year 2014.
Amedica Corporation Key Developments
Amedica Provides Sales Guidance for the Full Year 2015
Feb 9 16
Amedica provided sales guidance for the full year 2015. The company expects anticipates full year 2015 net sales to be at the high end of its previously stated guidance of $19 million to $19.5 million.
Amedica Regains Compliance With Nasdaq Listing Requirements
Feb 9 16
Amedica Corporation announced that it has regained compliance with Nasdaq's minimum bid price requirement. On February 8, 2016, the Company received a letter from the Nasdaq Listing Qualifications department stating that because the Company's closing bid price of its common shares has been at $1.00 per share or greater for 10 consecutive trading days, the Company has regained compliance with the minimum bid price requirement under Listing Rule 5450(a)(1).
Amedica Enhances Valeo II™ Product Family with the Addition of its Second Generation Cervical System
Jan 25 16
Amedica Corporation announced the release of its Valeo II™ C interbody fusion device system. The second generation cervical system will be commercially available mid-February 2016. The Valeo II C interbody fusion device, made entirely of Amedica’s micro composite silicon nitride biomaterial, offers a slim-profile design which improves intraoperative visibility for more exact placement and postoperative visibility, providing better assessment of successful fusion. The new design also includes directional teeth to resist expulsion, an anterior thread connection for improved inserter stability, and a 14x12mm footprint size for smaller patients. Accompanying the revised implants are new consolidated, single-level instrumentation sets with improved ergonomics and ease of use. The Valeo II C interbody fusion device is made of micro composite silicon nitride biomaterial, which offers a favorable environment for bone growth and osteointegration, when compared to competitive PEEK and titanium offerings. Valeo II silicon nitride interbody fusion devices are also semi-radiolucent with clearly visible boundaries in x-rays and produce no artifacts under MRI or CT scans. The combination of these properties is found only in Amedica's silicon nitride biomaterial technology. The Valeo C family of products is the first to receive FDA clearance for two-level cervical interbody cage indications. Valeo cervical fusion devices are indicated for use in skeletally mature patients with degenerative disc disease at one disc level or two contiguous levels and are designed for use with autograft or allograft to facilitate fusion.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries